ALLO vs V · rev $22.0K vs P/E 33, rev $40.00B
Allogene Therapeutics Inc (ALLO) versus Visa Inc. Class A (V) — a side-by-side from cached financials, not a winner call.
Allogene Therapeutics Inc (ALLO) is a biotechnology company listed on US.
Visa Inc. Class A (V) is a credit services company listed on US. It is led by Ryan McInerney.
Latest reported ALLO revenue for 2024-12-31 was $22.0K. Net income was -$257.6M. Revenue was down 76.8% from 2023-12-31 to 2024-12-31. ALLO currently screens at market cap $258.1M.
Latest reported V revenue for 2025-09-30 was $40.00B. Net income was $20.06B. V currently screens at market cap $659.78B and trailing P/E 33.5.
ALLO currently screens at market cap $258.1M. V currently screens at market cap $659.78B and trailing P/E 33.5.
Not investment advice. Open the ALLO and V stock pages for the full models.
Not investment advice.